InnoCan Pharma Corporation
INNO
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -571.38% | -275.07% | 67.06% | 87.09% | 85.69% |
| Total Depreciation and Amortization | 22.22% | -10.00% | 0.00% | -25.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 140.43% | 5,007.69% | -35.33% | -210.49% | -37.86% |
| Change in Net Operating Assets | 90.44% | 91.43% | 105.64% | 116.38% | -1,315.93% |
| Cash from Operations | 102.19% | 1.63% | 149.26% | 61.56% | -39.69% |
| Capital Expenditure | 33.33% | 66.67% | -150.00% | 55.56% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 33.33% | 33.33% | -100.00% | 822.22% | 81.25% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 50.00% | 20.00% | 20.00% | -20.00% | -20.00% |
| Issuance of Common Stock | -100.00% | -- | -- | -- | -48.16% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -- | -56.94% | -1.86% | -31.98% |
| Cash from Financing | -100.35% | 3,160.00% | -31.31% | -64.22% | -40.68% |
| Foreign Exchange rate Adjustments | -100.00% | 172.60% | -133.33% | -115.87% | 138.30% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 111.36% | 49.83% | 91.13% | 64.75% | -120.28% |